Akcea shows off what No­var­tis missed and what Pfiz­er gained, of­fer­ing more de­tails on PhII car­dio da­ta

Back in Jan­u­ary Io­n­is spin­off Akcea teased, in two press re­leas­es is­sued one week apart, topline da­ta sug­gest­ing its two up-and-com­ing an­ti­sense oligonu­cleotides can sig­nif­i­cant­ly slashed triglyc­erides as well as oth­er pro­teins tied with car­dio­vas­cu­lar dis­ease. At the vir­tu­al Eu­ro­pean So­ci­ety of Car­di­ol­o­gy, the biotech fi­nal­ly gets a chance to lay them all out.

As their names sug­gest, AKCEA-APOC­I­II-LRx and AKCEA-ANGPTL3-LRx (vu­panors­en) tar­get apolipopro­tein C-III (APOC-III) and an­giopoi­etin-like 3 (ANGPTL3), re­spec­tive­ly. In both Phase II stud­ies be­ing pre­sent­ed at ESC, in­ves­ti­ga­tors re­cruit­ed pa­tients with hy­per­triglyc­eridemia and chose fast­ing triglyc­eride lev­el as the pri­ma­ry end­point. Both cleared the bar with a clean safe­ty slate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER